Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Guardant Health Inc stake
total: 670
Viking Global Investors GH trades
- Total transactions:
- 17
- New positions:
- 1
- Sold out:
- 1
- Added:
- 7
- Reduced:
- 8
- Held since:
- 2019 Q3
- Held for:
- 16 quarters
- Latest activity:
- 2023 Q3
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any Guardant Health Inc (GH) shares. To date, the estimated cost basis is nearly $85.61 for "buy" trades and estimated average "sell" price is $53.06. Viking Global Investors first purchased GH in 2019 Q3, initially acquiring about 2.87M shares. Since the initial investment in Guardant Health Inc (GH), Viking Global Investors has made 16 more transactions.
When did Ole Andreas Halvorsen sell Guardant Health Inc (GH)?
Ole Andreas Halvorsen sold off the entire Guardant Health Inc (GH) position in 2023 Q3.
When did Ole Andreas Halvorsen buy Guardant Health Inc (GH)?
Ole Andreas Halvorsen first invested in Guardant Health Inc (GH) in 2019 Q3 at the reported quarter-end price of $63.83 per share.
What's the cost basis of Viking Global Investors's GH stake?
The estimated cost basis for Guardant Health Inc (GH) stake is around $85.61 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $85.61
- Weighted AVG sell price:
- $53.06
Ole Andreas Halvorsen's historical trades in Guardant Health Inc
17 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q3
|
0.00%
|
0
|
$35.80
|
|
-100% (-1,594,326)
|
-0.23%
|
|
2023 Q2
|
0.23%
|
1,594,326
|
$35.80
|
$57,076,871
|
-37.20% (-944,563)
|
-0.16%
|
|
2023 Q1
|
0.28%
|
2,538,889
|
$23.44
|
$59,511,558
|
-38.19% (-1,568,755)
|
-0.18%
|
|
2022 Q4
|
0.56%
|
4,107,644
|
$27.20
|
$111,727,917
|
+7.09% (+272,034)
|
+0.04%
|
|
2022 Q3
|
0.95%
|
3,835,610
|
$53.83
|
$206,471,000
|
-14.36% (-643,410)
|
-0.16%
|
|
2022 Q2
|
0.83%
|
4,479,020
|
$40.34
|
$180,684,000
|
-22.94% (-1,333,214)
|
-0.22%
|
|
2022 Q1
|
1.56%
|
5,812,234
|
$66.24
|
$385,002,000
|
+14.54% (+737,845)
|
+0.2%
|
|
2021 Q4
|
1.46%
|
5,074,389
|
$100.02
|
$507,540,000
|
+3.67% (+179,453)
|
+0.05%
|
|
2021 Q3
|
1.68%
|
4,894,936
|
$125.01
|
$611,916,000
|
+15.00% (+638,573)
|
+0.22%
|
|
2021 Q2
|
1.60%
|
4,256,363
|
$124.19
|
$528,598,000
|
+45.85% (+1,338,140)
|
+0.5%
|
|
2021 Q1
|
1.33%
|
$152.65
|
-17.44% (-616,619)
|
|||
|
2020 Q4
|
1.25%
|
$128.88
|
-8.30% (-320,051)
|
|||
|
2020 Q3
|
1.56%
|
$111.78
|
+25.64% (+786,720)
|
|||
|
2020 Q2
|
1.08%
|
$81.13
|
-19.23% (-730,277)
|
|||
|
2020 Q1
|
1.38%
|
$69.60
|
-0.95% (-36,303)
|
|||
|
2019 Q4
|
1.40%
|
$78.14
|
+33.41% (+960,325)
|
|||
|
2019 Q3
|
0.96%
|
$63.83
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.